Efficacy of Adherence-Enhancing Interventions for Immunosuppressive Therapy in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis Based on Randomized Controlled Trials

Yue-Xian Shi†, Chun-Xia Liu†, Fei Liu², Hai-Ming Zhang⁴, Ming-Ming Yu¹, Yin-Hui Jin⁵,⁶, Shao-Mei Shang¹* and Ying-Xin Fu⁷*

¹ School of Nursing, Peking University, Beijing, China, ² Department of Urinary Surgery, Peking University Third Hospital, Beijing, China, ³ School of Public Health, Peking University, Beijing, China, ⁴ Liver Transplantation Center, Clinical Center for Pediatric Liver Transplantation, National Clinical Research Center for Digestive Diseases, Beijing, China, ⁵ Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China, ⁶ Center for Evidence-Based and Translational Medicine, Wuhan University, Wuhan, China, ⁷ Department of Kidney Transplantation, Tianjin First Center Hospital, Tianjin, China

Background: Immunosuppressant non-adherence is a widespread problem among solid organ recipients. With the newly published clinical trials, the randomized controlled trials (RCTs) based systematic review of adherence-enhancing interventions on immunosuppressant adherence in solid organ recipients has not been completed. In this systematic review and meta-analysis, we compared the efficacy of adherence-enhancing interventions versus routine intervention, as performed with RCTs, on immunosuppressant adherence in solid organ transplantation recipients.

Methods: PubMed, Embase, Cochrane Library, CINAHL full text, and PsycINFO were searched from database inception to December 2019. This review was conducted following the PRISMA’s reporting guidelines and according to the principles recommended by Cochrane Handbook for Systematic Review.

Results: The search yielded 10,479 articles. A total of 27 articles (26 studies) with 715 participants were included in our analysis. Results from the meta-analysis revealed that as compared with that of the routine intervention group, the rates of overall adherence, dosing adherence, and timing adherence were significantly increased within the adherence-enhancing intervention group, with the pooled risk ratio (RR) of overall adherence = 1.17, [95% confidence interval (CI): 1.07 to 1.28; p = 0.0006]; RR of dosing adherence = 1.21 (95% CI: 1.08 to 1.36, p = 0.001); RR of timing adherence = 1.16 (95% CI: 1.03 to 1.29, p = 0.01). There was a significantly increased adherence score in the adherence-enhancing intervention group; however, no statistical significance on the immunosuppressant blood concentration was found between the two study groups.
This systematic review with meta-analysis was conducted following the PRISMA’s reporting guidelines and according to the principles recommended by Cochrane Handbook for Systematic Review. We have registered this meta-analysis on PROSPERO and the information is available at: http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42013006517. (registration number CRD42020172351).

Search Methods
Computerized databases and manual literature searches were the two main data sources. We conducted a systematic search of full-text articles in the PubMed, Embase, Cochrane Library, CINAHL full text, and PsycINFO databases. MeSH or EMTREE terms together with text words were searched in the PubMed, Cochrane Library, and Embase databases, and the text words were adopted in other databases. All of the database searches were supplemented with hand searches of relevant reviews, books, and grey literature in the ﬁelds of pharmacology, transplantation, and health economics. A list of the selected medical subject heading (MeSH) terms is presented in the supplemental materials. The full-text articles were then selected after the title and abstract screening.

A Systematic Review and Meta-Analysis

INTRODUCTION
Immunosuppressive therapy represents a life-long endeavor for solid organ transplant recipients. Unfortunately, these medication regimens often involve complex protocols, not only due to the number of pills required, but also to frequent dose adjustments based on blood level monitoring, side effects and rejection episodes.

As life-long immunosuppressive therapy is often critical for solid organ recipients and adherence to post-transplant immunosuppressants remains one of the most important factors for long-term allograft survival. Findings from several studies have indicated that immunosuppressant non-adherence is a pervasive problem among solid organ recipients. Non-adherence can be either deliberate or unintentional and include such events as not taking the medication as often as required, not in the exact dose and/or at the correct times (O’Carroll et al., 2006). The prevalence of immunosuppressant non-adherence can vary from 2 to 67% in solid organ transplant recipients (Martin and Gabardi, 2009; Zhang et al., 2019). The highest rate of immunosuppressant non-adherence was found in kidney transplant recipients with a prevalence of 36–55% (Gokoel et al., 2020), while that in adult heart transplant recipients is 34.1–41.1% (Leven et al., 2017) and 15–40% in liver transplants (Zhang et al., 2019).

Identification of effective intervention methods would be helpful to improve solid organ recipients’ immunosuppressant adherence. To date, considerable research has been devoted to systematic reviews and/or meta-analyses to determine whether interventions such as electronic monitoring feedback, pharmacist-led interventions, and cognitive education have a positive effect on immunosuppressant adherence. Results from two systematic reviews based on randomized controlled trials (RCTs) or prospective, retrospective, and cohort studies have found that adherence intervention could significantly improve immunosuppressive compliance within kidney transplant patients (Mathes et al., 2017; Zhu et al., 2017). Similarly, findings from a systematic review by Marcelino indicated that a psycho-educational intervention program exerted a positive impact on adherence in heart transplant patients (Marcelino et al., 2015). And a systematic review focusing on renal, heart, and liver transplant recipients revealed that a combination of interventions may be effective for long-term immunosuppressant adherence of solid organ recipients (De Bleser et al., 2009).

Based upon the results from these systematic reviews, the effectiveness of adherence-enhancing interventions on immunosuppressant therapy was expanded as achieved with adopting RCTs. In specific, three RCTs (Han et al., 2019; Levine et al., 2019; Geramita et al., 2020) adopted the mobile health or smartphone app as the main interventions to manage the immunosuppressive medication adherence in lung or kidney recipients, while Grady et al. conducted a pilot RCT study to determine whether a transition intervention could increase medication adherence in young heart transplant recipients (Grady et al., 2019).

Therefore, the new and RCTs based systematic review with meta-analysis would be necessary for further confirming the efficacy of adherence-enhancing interventions on immunosuppressant therapy in solid organ recipients. In this systematic review and meta-analysis, we compared the efficacy of adherence-enhancing interventions versus routine intervention, as performed with RCTs, on immunosuppressant adherence in solid organ transplantation recipients.

MATERIALS AND METHODS
This systematic review with meta-analysis was conducted following the PRISMA’s reporting guidelines and according to the principles recommended by Cochrane Handbook for Systematic Review. We have registered this meta-analysis on PROSPERO and the information is available at: http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42013006517. (registration number CRD42020172351).

Search Methods
Computerized databases and manual literature searches were the two main data sources. We conducted a systematic search of full-text articles in the PubMed, Embase, Cochrane Library, CINAHL full text, and PsycINFO databases. MeSH or EMTREE terms together with text words were searched in the PubMed, Cochrane Library, and Embase databases, and the text words were adopted in other databases. All of the database searches
were conducted from database inception to December 2019. The specific search strategy using PubMed as an example is in the Supplementary Material (Appendix 1, provided as online supplementary material). Manual searches of reference lists included additional relevant studies. We tried to identify unpublished studies by contacting experts who may have known about additional trials and retrieved the System for Information on Grey Literature database (http://opensigle.inist.fr/) to reduce publication bias.

Inclusion and Exclusion Criteria
We selected all publications and screened studies if they met the following criteria:

Participants
Trials consisting of patients receiving immunosuppressive therapy after solid organ transplant, including liver, kidney, heart, lung, and pancreases, were included in this study. Immunosuppression medications were considered as any one, or combination, of the following: tacrolimus, cyclosporine, mycophenolate-mofetil, and sirolimus. These were selected according to the immunosuppression medications reported in the included studies.

Intervention
Interventions were aimed at enhancing immunosuppressant adherence and were classified as: (1) directors of intervention were nurse, pharmacist, transplant/coordinator physicians, and multidisciplinary, etc.; and (2) intervention programs included any one, or combination, of the following: using mobile health system/app, self-management intervention, computer based/internet based intervention, comprehensive intervention approach combined with mobile health monitoring, etc., which were selected according to the interventions reported in the included studies.

Comparators
Routine intervention (or interventions different from the adherence-enhancing intervention).

Outcome Measures
The outcome of this systematic review was the adherence to the immunosuppressive therapy. However, as a variety of outcome measures were used for assessing adherence, differences in the definition of adherence existed among the studies. When reviewing outcome measures from the included studies the following measures regarding immunosuppressive therapy adherence emerged:

1. Overall adherence rate: This mainly included the adherence rate if the original article directly reported this outcome. Otherwise, we used the taking adherence rate, dosing adherence rate, or self-reported adherence rate (assessed by questionnaires) sequentially. Immunosuppressant adherence was estimated using electronic monitoring, refill records, or patient self-reports. If more than one method was reported, we used electronic monitoring because of the available objective data and then the refill record and patient self-reports. The rate of taking, dosing, and timing adherence were pooled if the data were provided in the included studies. Taking adherence was the proportion of prescribed doses taken. Dosing adherence was the proportion of a patient's actual immunosuppressant doses corresponding to the prescribed dosing regimen. Timing adherence was the proportion of prescribed doses taken within optimal inter-dose intervals.

2. Adherence score: When the score was used to express immunosuppressant adherence in the original studies, the score was pooled in our systematic review.

3. Immunosuppressant serum levels: We initially analyzed each study's mean serum immunosuppressant concentrations and the immunosuppressant concentration rates within, above, and below the target level. The coefficient of variation (CV) and standard deviation (SD) of immunosuppressant concentrations were analyzed if the original study reported these outcomes.

Types of Studies
RCT design studies with full text and English literature were included.

Study Selection
Two researchers independently screened all titles and abstracts and excluded studies that failed to satisfy the inclusion criteria. The full text of any published article that potentially satisfied the inclusion criteria was then reviewed to confirm its acceptance or rejection. Any disagreements about selection were resolved through discussion with a third reviewer. The list of potential studies was reviewed by two independent researchers. In cases of uncertainty regarding eligibility, a third reviewer was consulted.

Quality Assessment
The methodological quality of the included studies was assessed by two independent reviewers. We followed the criteria of the Cochrane Collaboration risk-of-bias tool as guides. The quality items assessed were selection bias (random sequence generation and allocation concealment), performance bias (blinding of participants, personnel, and outcome assessors), attrition bias, measurement bias, reporting bias, and other bias.

Data Extraction
The two researchers also developed a data extraction form, amended it as needed, and independently extracted the following data from each article: study characteristics (first author, publication year, and country), sample size, type of immunosuppression, outcomes and adherence assessment method, follow-up times, and interventions. We emailed study authors to obtain missing data or determine unclear information.

Synthesis
The risk ratio (RR) was used as the count data effect size for the adherence rate, while the standard mean difference (SMD) was used to assess the effects of continuous outcomes. A RR >1
indicated a favorable intervention. When statistical heterogeneity ($I^2 \geq 50\%$) was present among the studies, a random-effects model was used, otherwise, fixed-effects models were used. The source of statistical heterogeneity was evaluated using sensitivity analysis. Subgroup analyses by organ type, intervention director, follow-up time, adherence assessment method and intervention methods, and adherence assessment method were used to address clinical and methodological heterogeneity. Review Manager Version 5.3 (Copenhagen, Denmark) was used to synthesize and analyze the data.

RESULTS

Study Selection
The search yielded 10,479 articles; 50 full-text articles underwent further assessment and 23 were excluded. The excluded articles included non-randomized controlled trials ($n = 8$), opinions, editorials, and interventional strategies ($n = 4$), research protocols ($n = 3$), outcomes failing to show immunosuppressant adherence ($n = 7$), and an ongoing study ($n = 1$). The remaining 27 published papers were then included in our systematic review (Figure 1) (Chisholm et al., 2001; Hardstaff et al., 2002; Hardstaff et al., 2003; De Geest et al., 2006; DeVito Dabbs et al., 2009; Klein et al., 2009; Russell et al., 2011; Chisholm-Burns et al., 2013; McGillicuddy et al., 2013; Suhling et al., 2014; Garcia et al., 2015; Bessa et al., 2016; Breu-Dejean et al., 2016; DeVito Dabbs et al., 2016; Henriksson et al., 2016; Cukor et al., 2017; Dobbels et al., 2017; Harrison et al., 2017; Reese et al., 2017; Rosenberger et al., 2017; Schmid et al., 2017; Foster et al., 2018; Grady et al., 2019; Han et al., 2019; Levine et al., 2019; Geramita et al., 2020; Russell et al., 2020). As participants in two studies (Hardstaff et al., 2002; Hardstaff et al., 2003) were from the same cohort, 26 studies were then finally included in the systematic review.

Study Characteristics
Of the studies included studies, 14 were from the US (Chisholm et al., 2001; DeVito Dabbs et al., 2009; Russell et al., 2011; Chisholm-Burns et al., 2013; McGillicuddy et al., 2013; Suhling et al., 2014; DeVito Dabbs et al., 2016; Cukor et al., 2017; Reese et al., 2017; Rosenberger et al., 2017; Grady et al., 2019; Levine et al., 2019; Geramita et al., 2020; Russell et al., 2020) and Brazil (Bessa et al., 2016; Geramita et al., 2020), Germany (Klein et al., 2009; Schmid et al., 2017), Canada (Harrison et al., 2017;
Foster et al., 2018), and the UK (Hardstaff et al., 2002; Hardstaff et al., 2003) had two studies, respectively. The others originated from France (Breu-Dejean et al., 2016), Switzerland (De Geest et al., 2006), Sweden (Harrison et al., 2017), Belgium (Dobbels et al., 2017), and Korea (Han et al., 2019) (Table 1). A total of 2,678 participants were enrolled in these studies. The transplants conducted in these 27 studies included 18 kidney (Chisholm et al., 2001; Hardstaff et al., 2002; Hardstaff et al., 2003; De Geest et al., 2006; Russell et al., 2011; Chisholm-Burns et al., 2013; McGillicuddy et al., 2013; Garcia et al., 2015; Bessa et al., 2016; Breu-Dejean et al., 2016; Henriksson et al., 2016; Cukor et al., 2017; Reese et al., 2017; Schmid et al., 2017; Foster et al., 2018; Han et al., 2019; Levine et al., 2019; Russell et al., 2020), 5 lung (DeVito Dabbs et al., 2009; Suhling et al., 2014; DeVito Dabbs et al., 2016; Rosenberger et al., 2017; Geramita et al., 2020), 2 solid organ (Dobbels et al., 2017; Harrison et al., 2017), a heart (Grady et al., 2019), and a liver recipient (Klein et al., 2009). The follow-up periods ranged from 6 weeks to 15 months. The intervention programs for the two groups are summarized in Table S1 (provided as online Supplementary Material).

Methodological Quality

Figures 2, 3 present the results of the risk of bias assessment. As it was difficult to blind personnel/participants in interventions to improve adherence, blind personnel/participants in all of the included studies were assessed as a low risk of bias.

Effect of Intervention

Immunosuppressive Therapy Adherence as Assessed by Adherence Rate

1. Overall adherence rate: A total of 19 RCTs (Chisholm et al., 2001; Hardstaff et al., 2002; Hardstaff et al., 2003; De Geest et al., 2006; Klein et al., 2009; Chisholm-Burns et al., 2013; Suhling et al., 2014; Garcia et al., 2015; Bessa et al., 2016; Breu-Dejean et al., 2016; Cukor et al., 2017; Dobbels et al., 2017; Harrison et al., 2017; Reese et al., 2017; Schmid et al., 2017; Foster et al., 2018; Han et al., 2019; Geramita et al., 2020) reported immunosuppressant adherence rate, and we were able to extract 16 sets of analyzable data from 15 RCTs (Chisholm et al., 2001; Hardstaff et al., 2002; Klein et al., 2009; Chisholm-Burns et al., 2013; Garcia et al., 2015; Bessa et al., 2016; Breu-Dejean et al., 2016; Cukor et al., 2017; Dobbels et al., 2017; Harrison et al., 2017; Reese et al., 2017; Schmid et al., 2017; Foster et al., 2018; Han et al., 2019; Geramita et al., 2020) with 1,593 participants in the meta-analysis. A statistically significant heterogeneity was observed among these studies ($I^2 = 63\%$, $p = 0.0004$). Results from the meta-analysis showed that participants in the adherence-enhancing intervention groups showed significantly increased adherence rate as compared with those in the routine intervention groups with a pooled RR = 1.17 [95% confidence interval (CI): 1.07 to 1.28; $p = 0.0006$] (Figure 4). We did not include four RCTs in the pooled analysis as no analyzable data (Hardstaff et al., 2003; De Geest et al., 2006; Suhling et al., 2014) were available or they included comprehensive adherence rate in their analyses. (including immunosuppressants, attending clinic appointments, monitoring vital signs) (Rosenberger et al., 2017), which were then not appropriate for meta-analysis. Details regarding these studies are summarized in Table S2 (provided as online Supplementary Material).

2. The rate of taking, dosing, and timing adherence: There were two RCTs reporting taking (Klein et al., 2009; Foster et al., 2018), six reporting dose (Chisholm et al., 2001; Klein et al., 2009; Chisholm-Burns et al., 2013; Cukor et al., 2017; Dobbels et al., 2017; Reese et al., 2017), and four reporting timing adherence (Klein et al., 2009; Dobbels et al., 2017; Harrison et al., 2017; Foster et al., 2018). The meta-analysis showed that the dose and timing immunosuppressant adherence rates were significantly improved in participants receiving adherence-enhancing interventions, with pooled RR of dosing adherence = 1.21 (95% CI: 1.08 to 1.36, $p = 0.001$) and RR of timing adherence = 1.16 (95% CI: 1.03 to 1.29, $p = 0.01$) (Table 2 and Figure 5). Although there were three RCTs adopting taking (Hardstaff et al., 2003; De Geest et al., 2006; Han et al., 2019), two dose (Hardstaff et al., 2003; Han et al., 2019), and two timing adherence (De Geest et al., 2006; Han et al., 2019), no available data or unsuitable data were employed for the meta-analysis. Details on these outcomes are summarized in Table S2.

3. Adherence rate assessed by questionnaires: Thirteen RCTs (DeVito Dabbs et al., 2009; Suhling et al., 2014; Garcia et al., 2015; Bessa et al., 2016; Breu-Dejean et al., 2016; DeVito Dabbs et al., 2016; Dobbels et al., 2017; Reese et al., 2017; Schmid et al., 2017; Foster et al., 2018; Grady et al., 2019; Han et al., 2019; Geramita et al., 2020) assessed adherence rates using questionnaires. We were able to extract six sets of analyzable data from 5 RCTs to combine within our analyses (Bessa et al., 2016; Breu-Dejean et al., 2016; Reese et al., 2017; Grady et al., 2019). Results from this meta-analysis failed to achieve statistical significance between the two groups, with RR = 1.16 (95% CI: 0.94 to 1.44, $p = 0.17$) (Table 2 and Figure S1). Five RCTs (DeVito Dabbs et al., 2009; DeVito Dabbs et al., 2016; Schmid et al., 2017; Grady et al., 2019; Geramita et al., 2020) reported comprehensive adherence rates, which included not only immunosuppressant medications, but also clinic attendance and health monitoring, while three (Suhling et al., 2014; Dobbels et al., 2017; Foster et al., 2018) others did not provide analyzable data or median and mean, thus precluding the possibility for combining these statistics with other data. A summary of these studies is presented in Table S3 (provided as online Supplementary Material).

Blood Immunosuppressant Concentration

1. Tacrolimus level: Six RCTs (Garcia et al., 2015; Bessa et al., 2016; Cukor et al., 2017; Reese et al., 2017; Schmid et al., 2017; Grady et al., 2019) reported tacrolimus blood levels and the mean and standard differences were extracted from five (Garcia et al., 2015; Bessa et al., 2016; Cukor et al., 2017; Reese et al., 2017; Grady et al., 2019). A total of 469 patients participated in these five studies and the fixed-effects model was adopted because of an accepted heterogeneity among these
| Studies: Authors, Years, Country | Age (years) M ± SD median (IQR/range) | Sample size (I/C) | Type of transplantation | Immunosuppression | Adherence assessment |
|---------------------------------|----------------------------------------|------------------|-------------------------|------------------|---------------------|
| Bessa et al., 2016, Brazil      | I: 45.7 ± 11.6 C: 43.1 ± 12.5          | 64/62            | Kidney                  | 1. Mycophenolate  | 1. Coefficient of variation %CV |
|                                 |                                        |                  |                         | 2. Azathioprine   | 2. The percentage of patients who achieved tacrolimus target concentrations |
|                                 |                                        |                  |                         | 3. Sirolimus      | 3. Dose-corrected whole blood tacrolimus trough concentrations |
|                                 |                                        |                  |                         | 4. Tacrolimus     | 4. Assessment of patient adherence using BAASIS |
|                                 |                                        |                  |                         | 5. Mycophenolate mofetil |                     |
|                                 |                                        |                  |                         | 6. Everolimus     |                     |
|                                 |                                        |                  |                         |                  | Adapted questionnaire on adherence evaluation |
| Breu-Dejean et al., 2016, France | I: 49.7 ± 11.6 C: 47.9 ± 12.8          | 55/55            | Kidney                  | 1. Cyclosporine   | 1. Calculated Compliance rate (comparing patients’ monthly pharmacy refill records to the prescribed regimen documented in the patients’ medical records) |
|                                 |                                        |                  |                         | 2. Sirolimus      | 2. Serum concentrations of cyclosporine and tacrolimus |
|                                 |                                        |                  |                         | 3. Tacrolimus     | 3. Calculated the immunosuppressant therapy adherence rate by pharmacy refill records |
|                                 |                                        |                  |                         | 4. Mycophenolate mofetil | 4. Medication adherence by phone pill count |
|                                 |                                        |                  |                         | 5. Everolimus     | 5. Tacrolimus trough levels |
|                                 |                                        |                  |                         |                  | The Health Habits Assessment: determine post-transplant adherence in 10 areas: attending clinic appointments, completing blood work; monitoring home blood pressure and taking the primary immunosuppressant, etc. |
|                                 |                                        |                  |                         |                  | Reported of adherence by both patients and their primary family caregivers |
|                                 |                                        |                  |                         |                  | The Health Habits Survey was used to assess adherence to all elements of the medical regimen (e.g., taking medications, attending clinic appointments, completing lab work) |
|                                 |                                        |                  |                         |                  | Reported of adherence by both patients and their primary family caregivers |
|                                 |                                        |                  |                         |                  | Adherence to immunosuppressive regimen was measured by electronic monitor |
| De Vito Dabbs et al., 2009, USA  | 49.2 ± 10.2                            | 12/12            | Kidney                  | 1. Cyclosporine   | 1. Calculated Compliance rate (comparing patients’ monthly pharmacy refill records to the prescribed regimen documented in the patients’ medical records) |
|                                 |                                        |                  |                         | 2. Tacrolimus     | 2. Serum concentrations of cyclosporine and tacrolimus |
|                                 |                                        |                  |                         |                  | The Health Habits Survey was used to assess adherence to all elements of the medical regimen (e.g., taking medications, attending clinic appointments, completing lab work) |
|                                 |                                        |                  |                         |                  | Reported of adherence by both patients and their primary family caregivers |
|                                 |                                        |                  |                         |                  | Adherence to immunosuppressive regimen was measured by electronic monitor |
| De Vito Dabbs et al., 2016, USA  | I: 62 (51–67) C: 62 (51–68)            | 99/102           | Lung                    |                  | 1. The ABC taxonomy for medication adherence by electronic monitor |
|                                 |                                        |                  |                         |                  | 2. Poor implementation in relation to medication taking |
|                                 |                                        |                  |                         |                  | 3. BAASIS for adherence of the immunosuppressant |
|                                 |                                        |                  |                         |                  | 1. Taking adherence and timing adherence as measured using electronic monitoring; |
|                                 |                                        |                  |                         |                  | 2. Standard deviation of tacrolimus trough levels |
|                                 |                                        |                  |                         |                  | 3. Self-reported adherence: Medical Adherence Measure Medication Module (MAM-MM) |
| De Geest et al., 2006, Switzerland | 45.6 ± 1.2                             | 6/12             | Kidney                  | 1. Cyclosporine   | 1. Adherence of immunosuppressive therapy; using Immunosuppressant Therapy Adherence Scale |
|                                 |                                        |                  |                         | 2. Sirolimus      | 2. Adherence rate |
|                                 |                                        |                  |                         | 3. Tacrolimus     | 3. Serum levels of immunosuppressant drugs |
|                                 |                                        |                  |                         | 4. Mycophenolate mofetil | 1. Health Habits Survey: taking the primary immunosuppressant, taking other medications; |
|                                 |                                        |                  |                         | 5. Everolimus     | 2. Non-adherence was assessed by combination of patient and family caregiver report |
|                                 |                                        |                  |                         |                  | Tacrolimus      |
| Dobbs et al., 2017, Belgium     | I: 56.1 ± 11.7 C: 56.2 ± 11.8          | 103/102          | Heart, Liver and Lung   | Tacrolimus       | 1. The ABC taxonomy for medication adherence by electronic monitor |
| Foster et al., 2018, Canada     | I: 15.8 (13.3–17.5) C: 15.5 (13.2–17.4) | 72/88            | Kidney                  | Tacrolimus       | 2. Poor implementation in relation to medication taking |
| Garcia et al., 2015, Brazil     | I: 46.00 ± 14.1 C: 49.29 ± 12.1        | 55/56            | Kidney                  | 1. Cyclosporine   | 3. BAASIS for adherence of the immunosuppressant |
|                                 |                                        |                  |                         | 2. Sirolimus      | 1. Taking adherence and timing adherence as measured using electronic monitoring; |
|                                 |                                        |                  |                         | 3. Tacrolimus     | 2. Standard deviation of tacrolimus trough levels |
|                                 |                                        |                  |                         | 4. Mycophenolate mofetil | 3. Self-reported adherence: Medical Adherence Measure Medication Module (MAM-MM) |
| Geramita et al., 2020, USA      | I: 56.2 ± 12.3 C: 56.0 ± 14.2          | 47/58            | Lung                    | Unclear          | 1. Health Habits Survey: taking the primary immunosuppressant, taking other medications; |
|                                 |                                        |                  |                         |                  | 2. Non-adherence was assessed by combination of patient and family caregiver report |
| Grady et al., 2019, USA         | I: 21.3 ± 3.2 C: 21.5 ± 3.3           | 43/45            | Heart                   | Tacrolimus       | 1. Tacrolimus levels |
| Han et al., 2019, Korea         | I: 45 (35–54) C: 43 (30–52)           | 70/66            | Kidney                  | Tacrolimus       | 2. Self-report of adherence |
| Hardstuff et al., 2002, United Kingdom | Not mentioned                       | 75/25            | Kidney                  | Unclear          | Multidimensional Adherence by electric monitor |
| (Continued)                     |                                        |                  |                         |                  |                     |

Frontiers in Pharmacology | www.frontiersin.org 6 October 2020 | Volume 11 | Article 578887
### TABLE 1 | Continued

| Studies: Authors, Years, Country | Age (years) M ± SD median (IQR/range) | Sample size (I/C) | Type of transplantation | Immunosuppression | Adherence assessment |
|---------------------------------|--------------------------------------|-------------------|-------------------------|-------------------|----------------------|
| Hardstaff et al., 2002, United Kingdom | Not mentioned | 23/25 | Kidney | Unclear | The compliance in the time period |
| Harrison et al., 2017, Canada | I: 48.1 ± 13.7 C: 49.6 ± 12.4 | 126/120 | Heart, kidney, kidney-pancreas, liver, lung, liver-pancreas | 1. Tacrolimus 2. Cyclosporine | For each immunosuppressant, the number of doses missed or taken late in the last week was collected via patient self-report. |
| Henriksson et al., 2016, Sweden | I: 48.1 ± 13.7 C: 49.6 ± 12.4 | 40/40 | Kidney | 1. Tacrolimus 2. Cyclosporine 3. Sirolimus | Immunosuppressive adherence: Patients skipped their medicine dose, the number of missed doses; outpatient follow-up visits recorded by electronic medication dispenser |
| Klein et al., 2009, Germany | I: 52.8 (28–65) C: 50.1 (30–63) | 24/24 | Liver | Not mentioned | 1. Patients’ compliance with the immunosuppressive therapy was assessed by medication event monitoring systems 2. Calculated the compliance rates 3. Immunosuppressant serum concentrations 4. Patients were asked in writing how often they forgot to take a dose of their immunosuppressant during the last 4 weeks. |
| Levine et al., 2019, USA | I (Mobile app): 52 C: 53 | 38/20/50 | Kidney | 1. Tacrolimus 2. Mycophenolic acid | Immunosuppressive medication adherence: coefficient of variability (SD/mean tacrolimus) × 100 |
| McGillicuddy et al., 2013, USA | I: 42.44 C: 57.6 | 9/10 | Kidney | Not mentioned | 1. Calculation of medication adherence score by the data form Prototype mHealth System |
| Reese et al., 2017, USA | I: 50 ± 12 C: 50 ± 11 | 40/39/38 | Kidney | Tacrolimus | 1. Adherence according to wireless Electronic pill bottle |
| | C: 49 ± 11 | | | | 2. Blood Trough Concentrations |
| | | | | | 3. Self-rated Adherence using the BAASIS adherence questionnaire |
| Rosenberger et al., 2017, USA | I: 57 ± 13 C: 58 ± 14 | 96/102 | Lung | Not mentioned | 4. Pharmacist Assessment |
| Russell et al., 2011, USA | I: 55 C: 44 | 8/7 | Kidney | Not mentioned | 1. Self-report adherence 2. Collateral (family caregiver) report using the Health Habits Assessment Instrument |
| Russell et al., 2020, USA | I: 53 ± 11.2 C: 50 ± 9.7 | 45/44 | Kidney | Not mentioned | Medication non-adherence measured by Medication Event Monitoring System (adherence score) |
| Schmid et al., 2017, Germany | I: 46 (18–59) C: 51 (19–66) | 23/23 | Living donor | 1) Tacrolimus 2) Mycophenolic acid | 1. Average 6-month immunosuppressive medication adherence rate by the Medication Event Monitoring System SmartCap 2. Adherence at 12 months: 1) Composite adherence score: by using BAASIS 2) Composite adherence percentage: Collateral reports (physicians, nurses) and the target tacrolimus trough levels |
| Suhling et al., 2014, USA | I: 52 (35.9, 57.6) C: 45 (33.3, 53.9) | 32/32 | Lung | 1. Cyclosporine 2. Tacrolimus | 1. BAASIS for medication intake adherence 2. Percentage of calcineurin inhibitor trough levels 3. Physicians’ valuation of adherence |

**BAASIS:** Basel assessment of adherence with immunosuppressive medication scales; M, mean; SD, standard deviation; IQR, interquartile range; I, intervention group; C, control group.

---

**Table 2 and Figure S2**: The study of Schmid et al. (2017) was not included in this analysis as a comprehensive adherence rate (combination of tacrolimus trough levels, collateral reports, and self-reported adherence rates) was used for analysis in that study (Table S3).

2. Coefficient of variation and standard deviation for blood tacrolimus or cyclosporine levels: The coefficient of variation and standard deviation were also used to estimate immunosuppressive therapy adherence in three (Bessa et al., 2016; Reese et al., 2017; Levine et al., 2019) and two RCTs (Harrison et al., 2017; Foster et al., 2018) respectively. Meta-analyses were not conducted because of the small number of studies (I² = 0%, p = 0.90). The pooled analysis showed that there was no significant difference between the two groups, with pooled SMD = −0.04 (95% CI: −0.23 to 0.14, p = 0.63) (Table 2 and Figure S2). The study of Schmid et al. (2017) was not included in this analysis as a comprehensive adherence rate (combination of tacrolimus trough levels, collateral reports, and self-reported adherence rates) was used for analysis in that study (Table S3).

3. Rate of immunosuppressant blood levels within the target range: This variable was reported in seven RCTs (Chisholm et al., 2001; Klein et al., 2009; Suhling et al., 2014; Bessa et al., 2016; Harrison et al., 2017; Reese et al., 2017; Grady et al., 2019), and the data from three studies (Bessa et al., 2016; Harrison et al., 2017; Grady et al., 2019) were combined. We used the random-effects model because of significant heterogeneity among these studies (I² = 63%, p = 0.07). Results of this meta-analysis found no significant group differences on the rate of immunosuppressant blood levels within the target range, with the pooled RR = 1.00 (95% CI: 0.69 to 1.46, p = 1.00) (Table 2 and Figure S3). The four other studies were not included in the pooled analysis because they...
reported both the tacrolimus and cyclosporine target range (Chisholm et al., 2001), adopting the mean, standard difference, or median and interquartile as statistics (Suhling et al., 2014; Reese et al., 2017) and using the percentage of blood test times meeting the target value (Klein et al., 2009). Bessa (Bessa et al., 2016) and Klein (Klein et al., 2009) analyzed the rate of immunosuppressant blood levels above or below the target range, and the results of meta-analysis did not find statistical significance between the groups (Table S4 and Figure S3).

4. Adherence Score: Four RCTs (Russell et al., 2011; McGillicuddy et al., 2013; Garcia et al., 2015; Russell et al., 2020) assessed immunosuppressive therapy using adherence score. These studies included 232 participants and the random-effects model was adopted because of significant heterogeneity among these studies ($I^2 = 69\%$, $p = 0.02$). Significant differences in the pooled analysis were obtained between the two groups, with the pooled SMD = 1.14 (95% CI: 0.52 to 1.75, $p = 0.0003$) (Table 2 and Figure S4).

Subgroup Analysis and Sensitivity Analysis

Results from the sensitivity analysis did not reveal any changes in the results when excluding studies with a high risk of bias or a large effect size to test the robustness of the results. Subgroup analyses were separated by organ transplant type (kidney, lung, etc.), intervention director (pharmacist, nurse, or coordinator), follow-up time, adherence assessment method (self-reported or electronic monitoring), and intervention methods. With respect to the organ type, the effect of adherence-enhancing intervention on adherence rate included 12 studies with kidney recipients, one with liver, one with lung, and two studies included several organ types (e.g. heart/lung/kidney/liver-kidney/kidney-pancreases). Due to the small number of studies on liver, lung, heart or combined organ recipients, these data were pooled to generate two subgroups for comparison (kidney and others). Results of the meta-analysis for these two subgroups indicated that the adherence rate was significantly increased in both groups in response to the adherence-enhancing intervention. Multidisciplinary-led interventions displayed a statistically increased adherence rate after receiving the adherence-enhancing intervention (Table 2 and Figures S5, S6). When assessed at a $\geq 6$ month follow-up period, a significantly increased immunosuppressive therapy adherence rate was present in the intervention group (Table 2 and Figure S7). The results also found that the outcomes whether assessed using electric monitoring or self-reporting displayed significant differences between the groups (Table 2 and Figure S8). We did not find that intervention together with mobile health or adopting electronic monitoring only could be more effective than control groups (Table 2 and Figure S9).

DISCUSSION

Summary of Main Findings

Immunosuppressive therapy is critical for solid organ transplant patients and poor adherence to immunosuppressive therapy can negatively impact the long-term outcomes of these patients.
Accordingly, improving drug compliance represents an important component for the long-term care of these patients after surgery. In this report, we provide the first systematic review and meta-analysis on the effects of adherence interventions as based on RCT studies. Our meta-analysis revealed that adherence-enhancing interventions can result in significant increases in total adherence, medication dosing, and timing adherence rates, as well as improvements in immunosuppressive therapy adherence scores. Patients receiving kidney transplants have been shown to benefit from interventions and a multidisciplinary-led intervention provided an effective approach to educate and monitor patients. These benefits resulting from interventions have been demonstrated under conditions where outcomes were assessed using either electric monitoring or self-reporting. Moreover, effects of adherence-enhancing intervention persist, as determined after 6 months post-intervention and were sustained for a year. At present, there is insufficient evidence to assess which type of intervention (mobile health, cognitive, or behavioral) may be maximally effective.

Several systematic reviews have focused on the effectiveness of interventions such as behavioral and cognitive interventions or medication knowledge improvement on adherence of immunosuppressive therapy patients. Of these, only one study pooled the outcomes of their findings. The results of this study demonstrated that adherence rate was significantly increased in kidney transplant patients receiving intervention programs designed to increase their immunosuppressive adherence as compared with that of a control group (Zhu et al., 2017). A systematic review from the Joanna Briggs Institute (JBI) also provided weak evidence supporting the effectiveness of interventions to manage adherence in heart or heart-lung transplantation patients (Guimarães Marcelino and da Cruz, 2013). De Bleser et al. examined the effectiveness of adherence-enhancing interventions for solid organ (renal, heart, and liver) transplant recipients, and the results of their systematic review indicated that a combination of interventions in a team approach might be effective over the long term (De Bleser et al., 2009).

Adherence to immunosuppressive interventions implies not only intake of medicines, but also taking the correct dose of immunosuppressants at the appropriate time. A number of approaches are currently used to estimate adherence to immunosuppressive interventions. For example, calculating adherence rates have used the data from electronic monitoring, pill accounts, self-reports or collateral reports, measurement of
TABLE 2 | The results of meta-analysis for the effectiveness of adherence enhancing interventions on adherence of immunosuppressive therapy.

| Adherence rate | No. of included studies | Sample size in meta-analysis | Heterogeneity | Effect sizes |
|----------------|-------------------------|-------------------------------|---------------|-------------|
| Overall adherence rate | 15 | 1,593 | 63% | 0.0004 | 1.17 | 1.07, 1.28 | 3.45 | 0.0006 |
| Taking adherence rate | 2 | 179 | 14% | 0.28 | 1.08 | 0.96, 1.22 | 1.25 | 0.21 |
| Doing adherence rate | 6 | 552 | 50% | 0.06 | 1.21 | 1.08, 1.36 | 3.27 | 0.001 |
| Timing adherence rate | 4 | 534 | 35% | 0.21 | 1.16 | 1.03, 1.29 | 2.55 | 0.01 |

| Adherence rate by organ type | | | | | |
| Kidney | 11 | 1,096 | 64% | 0.001 | 1.23 | 1.08, 1.41 | 3.06 | 0.002 |
| Others | 4 | 497 | 43% | 0.16 | 1.10 | 1.00, 1.22 | 2.02 | 0.04 |

| Adherence rate by interventional director | | | | | |
| Multidisciplinary | 5 | 560 | 28% | 0.23 | 1.45 | 1.25, 1.67 | 5.02 | <0.00001 |
| Pharmacist | 5 | 541 | 25% | 0.26 | 1.07 | 0.96, 1.19 | 1.23 | 0.22 |
| Other | 5 | 492 | 54% | 0.07 | 1.08 | 0.95, 1.22 | 1.18 | 0.24 |

| Adherence rate by different assessment method | | | | | |
| Electronic monitor | 7 | 793 | 47% | 0.07 | 1.16 | 1.04, 1.30 | 2.62 | 0.009 |
| Self-reported or collateral report | 7 | 822 | 71% | 0.002 | 1.18 | 1.02, 1.36 | 2.26 | 0.02 |
| Others | 2 | 79 | 92% | 0.0004 | 1.39 | 0.54, 3.55 | 0.68 | 0.49 |

| Adherence rate by intervention way | | | | | |
| Including mobile health | 3 | 265 | 66% | 0.05 | 1.19 | 0.83, 1.70 | 0.94 | 0.35 |
| Electronic medication only | 2 | 246 | 75% | 0.02 | 1.21 | 0.79, 1.84 | 0.88 | 0.38 |
| Others | 9 | 1,039 | 62% | 0.007 | 1.17 | 1.05, 1.31 | 2.93 | 0.003 |

| Adherence rate by follow-up time | | | | | |
| ≤3-month | 7 | 866 | 69% | 0.002 | 1.13 | 0.98, 1.30 | 1.73 | 0.08 |
| >3 to ≤6-month | 4 | 527 | 46% | 0.14 | 1.22 | 1.05, 1.42 | 2.60 | 0.009 |
| >12-month | 5 | 562 | 46% | 0.12 | 1.13 | 1.02, 1.25 | 2.37 | 0.02 |

| Adherence rate assessed by questionnaire | | | | | |
| Tocilizumab concentration | 5 | 469 | 0% | 0.90 | -0.04 | -0.23, 0.14 | 0.49 | 0.63 |
| Within target | 3 | 303 | 63% | 0.07 | 1.00 | 0.69, 1.46 | 0.00 | 1.00 |
| Above target | 2 | 321 | 84% | 0.01 | 0.68 | 0.27, 1.72 | 0.81 | 0.42 |
| Below target | 2 | 321 | 93% | 0.0001 | 0.64 | 0.06, 6.52 | 0.38 | 0.71 |
| Adherence score | 4 | 232 | 69% | 0.02 | 1.14 | 0.52, 1.75 | 3.61 | 0.0003 |

RR, risk ratio; SMD, standard mean difference; CI, confidence interval.

FIGURE 5 | Forest plot of different adherence rate. Risk Ratio (RR) with 95% confidence interval (CI) between the adherence enhancing intervention group and routine intervention groups.
blood immunosuppressant concentrations, and self-reported questionnaires. While electronic monitoring is considered as the gold standard for assessing non-adherence, it may not be feasible in daily clinical practice. Self-reporting alone might cause over- or under-reporting (Foster et al., 2018), so the information derived from various sources (self-reports and collateral reports) is more recommended than single-measurement methods (De Geest et al., 2006; Foster et al., 2018). Blood immunosuppressant concentrations, especially tacrolimus levels, were also used to reflect adherence in many studies, but may be influenced by variations in metabolism and other confounding factors (Burra et al., 2011). Results of our meta-analysis demonstrated that adherence-enhancing intervention could be effective for producing adherence to immunosuppressive therapy, as indicated from results obtained using electronic monitoring and self-reports and/or collateral adherence reports. We did not find a significant difference in outcomes related to blood immunosuppressant levels between the groups, possibly due to the small sample size of studies in the pooled analysis. With respect to self-report questionnaires, BAASIS was primarily used in the included studies, which was specific for adherence to immunosuppressive therapy and administration. As the number of studies included was quite limited, BAASIS in this meta-analysis did not detect any differences in adherence between the two study groups.

With the advent of smartphones and mobile medical devices, mobile health (mHealth) has become a popular method for medical staff to manage patient therapy. Mobile health can serve as an adjuvant method for delivering health education information, sending reminders to patients to take their medicine, and implementing online education. A systematic review indicated that information technology-based interventions such as mobile health/personal digital assistants (PDAs), computer systems, and multi-components have the potential to improve self-management in adolescents and young adult kidney transplant recipients (Ganjali et al., 2019). However, due to the limited number of studies and absence of sufficient data, our meta-analysis did not find significant results demonstrating that interventions together with mobile health or electronic monitoring were more effective than the routine intervention. The challenging nature of immunosuppressive therapy underscores the need for long-term and persistent interventions.

A combination of multiple interventions may be necessary to maintain adherence. As shown in Table S1, adherence-enhancing interventions for immunosuppressive therapy included increasing knowledge related to immunosuppressants, visiting physicians at the appointed times, improving patient behavior, and reminding patients to take their medications in an accurate and timely manner. Our meta-analysis confirmed that interventions led by a multidisciplinary team could improve the immunosuppressive therapy adherence rate for solid organ recipients. Therefore, we believe that a multidisciplinary team approach is a priority for achieving a maximal rate of adherence.

Limitations
There are limitations to this study that merit consideration. First, although many published studies explored adherence-enhancing interventions on immunosuppressive therapy, only a few published studies exist with RCT designs. This resulted in a limited number of studies with small sample sizes which could be included within our systematic review. Moreover, the outcome data in several of these studies were presented using charts or textual descriptions only, and data that needed to be synthesized or analyzed were unable to be extracted. Second, the exact definition of adherence to immunosuppressants varied among studies, which may have weakened the strength of the evidence garnered. Third, with the exception of the overall adherence rate, subgroup analyses were not included in other outcomes (dosing adherence, timing adherence, and blood tacrolimus level) because of the limited number of studies. Fourth, most of the studies included focused on adherence in kidney recipients, with studies involving other solid organs (liver, lungs, heart, and pancreases) being substantially less represented in these analyses. In this way, it is not possible to provide evidence regarding the effectiveness of adherence-enhancing interventions for liver/lung/heart/pancreases and other combined organ transplantation recipients. Finally, it is also important to note that due to a lack of recent studies using RCTs, some of the included studies in this systematic were published more than 10 years and some almost 20 years ago, resulting in the inclusion of some references which appear quite dated.

CONCLUSION
Adherence-enhancing interventions can be considered effective methods of improving adherence to immunosuppressive therapy. We recommend multidisciplinary team-led, life-long, comprehensive interventions together with mobile health for the administration of immunosuppressive therapy to solid organ recipients. For future studies, RCTs with a larger sample size and long-term follow-up are necessary to overcome the shortcomings of current trials. The definitions of adherence and non-adherence should be consistent and clearly described.

AUTHOR CONTRIBUTIONS
Y-XS, C-XL, and YXF: Made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data. Y-XS, C-XL, FL, M-MY, and Y-HJ: Involved in drafting the manuscript or revising it critically for important intellectual content. Y-XS, C-XL, FL, H-MZ, and S-MS: Given final approval of the version to be published. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content. Y-XS, S-MS, and Y-XF: Agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors contributed to the article and approved the submitted version.
FUNDING

This work was supported by National Natural Science Foundation of China (No. 71603272 and No. 71974008) and China Postdoctoral Science Foundation (No. 2018M64114 and No. 2020T130029).

REFERENCES

Bessa, A. B., Felipe, C. R., Hannun, P., Sayuri, P., Felix, M. J., Ruppel, P., et al. (2016). Prospective Randomized Trial Investigating the Influence of Pharmaceutical Care on the Intra-Individual Variability of Tacrolimus Concentrations Early after Kidney Transplant. Ther. Drug Monit. 38, 447–455. doi: 10.1097/FTD.0000000000000299

Breu-Dejean, N., Driot, D., Dupouy, J., Lapereyre-Mestre, M., and Rostaing, L. (2016). Efficacy of Psychoeducational Intervention on Allograft Function in Kidney Transplant Patients: 10-Year Results of a Prospective Randomized Study. Exp. Clin. Transplant. 14, 38–44. doi: 10.6002/eclt.2015.0151

Burra, P., Germani, G., Gnoato, F., Lazzaro, S., Russo, F. P., Cillo, U., et al. (2011). Adherence in liver transplant recipients. Liver Transplant. 17, 760–770. doi: 10.1002/lt.22294

Chisholm, M. A., Mulloy, L. L., Jagadeesan, M., and Dipro, J. T. (2001). Impact of clinical pharmacy services on renal transplant patients’ compliance with immunosuppressive medications. Clin. Transplant. 15, 330–336. doi: 10.1034/j.1399-0012.2001.150605.x

Chisholm-Burns, M. A., Spoive, C. A., Graff Zivin, J., Lee, J. K., Sredzinski, E., and Tolley, E. A. (2013). Improving outcomes of renal transplant recipients with behavioral adherence contracts: a randomized controlled trial. Am. J. Transplant. 13, 2364–2373. doi: 10.1111/ajt.12341

Cukor, D., Ver Halen, N., Pencille, M., Tedla, F., and Salifu, M. (2017). A Pilot Randomized Controlled Trial to Promote Immunosuppressant Adherence in Adult Kidney Transplant Recipients. Nephron 135, 6–14. doi: 10.1159/000448627

De Bleser, L., Matteson, M., Dobbels, F., Russell, C., and De Geest, S. (2009). Interventions to improve medication-adherence after transplantation: a systematic review. Transpl. Int. 22, 780–797. doi: 10.1111/j.1399-0012.2009.00881.x

De Geest, S., Schafer-Keller, P., Thannberger, N., Kofer, S., Bock, C., Cukor, D., Ver Halen, N., Pencille, M., Tedla, F., Salifu, M., et al. (2017). Efﬁcacy of a Mobile Medication Manager Application to improve adherence with immunosuppressive therapy in renal transplant recipients: A randomized controlled trial. PLoS One 12, e0224595. doi: 10.1371/journal.pone.0224595

Garcia, M. F. F. M., Bravin, A. M., Garcia, P. D., Contti, M. M., Nga, H. S., Takase, H. M., et al. (2015). Behavioral measures to reduce non-adherence in renal transplant recipients: a prospective randomized controlled trial. Int. Urol. Nephrol. 47, 1899–1905. doi: 10.1007/s11255-015-1104-z

Hardstaff, R., Green, K., and Talbot, D. (2003). Measurement of compliance with immunosuppressive medications. Clin. Transplant. 17, 2364–2373. doi: 10.1034/j.1399-0012.2001.150605.x

Geramita, E. M., Devito Dabb, A. J., Dimartini, A. F., Pilewski, J. M., Switzer, G. E., Poslusny, D. M., et al. (2020). Impact of a Mobile Health Intervention on Long-Term Nonadherence After Lung Transplantation: Follow-up After A Randomized Controlled Trial. Transplantation 104, 640–651. doi: 10.1097/ TP.0000000000002872

Supplementary Material

The Supplementary Material for this article can be found online at: http://www.frontiersin.org/articles/10.3389/fphar.2020.578887/full#supplementary-material

Guimarães Marcelino, C. A., and da Cruz, D. M. (2013). The effectiveness of interventions to manage treatment adherence in adult heart transplant patients: A systematic review protocol. JBl Database Syst. Rev. Implement. Rep. 11, 306–318. doi: 10.11124/01938924-201311010-00005

Hann, A., Min, S. I., Ahn, S., Min, S. K., Hong, H. J., Han, N., et al. (2019). Mobile medication manager application to improve adherence with immunosuppressive therapy in renal transplant recipients: A randomized controlled trial. J. Cardiac Fail. 25, 948–958. doi: 10.1016/j.cardfail.2019.06.011

Harrison, J. J., Badr, S., Hamandi, B., and Kim, S. J. (2017). Randomized Controlled Trial of a Computer-Based Education Program in the Home for Solid Organ Transplant Recipients: impact on Medication Knowledge, Satisfaction, and Adherence. Transplantation 101, 1336–1343. doi: 10.1097/ TP.0000000000001279

Henriksson, J., Tydén, G., Höijer, J., and Wadström, J. (2016). A prospective randomized trial on the effect of using an electronic monitoring drug dispensing device to improve adherence and compliance. Transplantation 100, 203–209. doi: 10.1097/TP.0000000000000971

Higgins, J., and Green, S. (2008). “Cochrane handbook for systematic reviews of interventions. version 5.0. 1,” in The Cochrane Collaboration. Available at: http://www.cochrane-handbook.org.

Klein, A., Otto, G., and Kramer, I. (2009). Impact of a pharmaceutical care program on liver transplant patients’ compliance with immunosuppressive medication: a prospective, randomized, controlled trial using electronic monitoring. Transplantation 87, 839–847. doi: 10.1097/TP.0b013e318199d122

Leven, E. A., Annunziato, R., Helcer, J., Lieber, S. R., Knight, C. S., Wlodarkiewicz, C., et al. (2017). Medication adherence and rejection rates in older vs younger adult liver transplant recipients. Clin. Transplant. 31, e12981. doi: 10.1111/ ctt.12981

Levine, D., Torabi, J., Choinski, K., Rocca, J. P., and Graham, J. A. (2019). Clin. Pulm. Med. 18, 257–264. doi: 10.1097/CPM.0000000000000519

Maher, T. M. (2011). Current and future therapies for idiopathic pulmonary fibrosis. Clin. Pulm. Med. 18, 257–264. doi: 10.1097/CPLM.0b013e3182350bb4

Marcelino, C. A., Díaz, L. J., and Da Cruz, D. M. (2015). The effectiveness of interventions in managing treatment adherence in adult heart transplant patients: a systematic review. JBI Database Syst. Rev. Implement. Rep. 13, 279–308. doi: 10.11124/01938924-201513090-00020
Martin, S., and Gabardi, S. (2009). Medication adherence in solid organ transplant recipients and the impact of clinical pharmacy services. *J. Pharm. Pract. Res.* 39, 257–258. doi: 10.1002/j.2055-2335.2009.tb00466.x

Mathes, T., Großpietsch, K., Neugebauer, E. A. M., and Pieper, D. (2017). Interventions to increase adherence in patients taking immunosuppressive drugs after kidney transplantation: A systematic review of controlled trials. *Syst. Rev.* 6, 236. doi: 10.1186/s13643-017-0633-1

McGillicuddy, J. W., Gregoski, M. J., Weiland, A. K., Rock, R. A., Brunner-Jackson, B. M., and Patel, S. K. (2013). Mobile health medication adherence and blood pressure control in renal transplant recipients: a proof-of-concept randomized controlled trial. *JMIR Res. Protoc.* 2, e32. doi: 10.2196/resprot.2633

O’Carroll, R. E., Mcgredor, L. M., Swanson, V., Masterton, G., and Hayes, P. C. (2006). Adherence to medication after liver transplantation in Scotland: A pilot study. *Liver Transplant.* 12, 1862–1868. doi: 10.1002/lt.20828

Reese, P. P., Bloom, R. D., Trof-Clark, J., Mussell, A., Leidy, D., Levsky, S., et al. (2017). Automated Reminders and Physician Notification to Promote Immunosuppression Adherence Among Kidney Transplant Recipients: a Randomized Trial. *Am. J. Kidney Dis.* 69, 400–409. doi: 10.1053/j.ajkd.2016.10.017

Rosenberger, E. M., Devito Dabbs, A. J., Dimartini, A. F., Landsittel, D. P., Pilewski, J. M., and Dew, M. A. (2017). Long-Term Follow-up of a Randomized Controlled Trial Evaluating a Mobile Health Intervention for Self-Management in Lung Transplant Recipients. *Am. J. Transplant.* 17, 1286–1293. doi: 10.1111/ajt.14062

Russell, C., Conn, V., Ashbaugh, C., Madsen, R., Wakefield, M., Webb, A., et al. (2011). Taking immunosuppressive medications effectively (TIMELink): a pilot randomized controlled trial in adult kidney transplant recipients. *Clin. Transplant.* 25, 864–870. doi: 10.1111/j.1399-0012.2010.01358.x

Russell, C. L., Hathaway, D., Remy, I. M., Aholt, D., Clark, D., Miller, C., et al. (2020). Improving medication adherence and outcomes in adult kidney transplant patients using a personal systems approach: systemCHANGETM results of the MAGIC randomized clinical trial. *Am. J. Transplant.* 20, 125–136. doi: 10.1111/ajt.15528

Schmidt, C., Hils, S., Kramer-Zucker, A., Bogatyreva, L., Haushcke, D., De Geest, S., et al. (2017). Telemedically Supported Case Management of Living-Donor Renal Transplant Recipients to Optimize Routine Evidence-Based Aftercare: A Single-Center Randomized Controlled Trial. *Am. J. Transplant.* 17, 1594–1605. doi: 10.1111/ajt.14138

Suhling, H., Rademacher, J., Zinowsky, I., Fuge, J., Greer, M., Warnecke, G., et al. (2014). Conventional vs. tablet computer-based patient education following lung transplantation—a randomized controlled trial. *PLoS One* 9, e90828. doi: 10.1371/journal.pone.0090828

Zhang, M., Zhou, H., Nelson, R. S., Han, Y., Wang, Y., Xiang, H., et al. (2019). Prevalence and Risk Factors of Immunosuppressant Nonadherence in Heart Transplant Recipients: A Single-Center Cross-Sectional Study. *Patient Prefer. Adherence* 13, 2185–2193. doi: 10.2147/PPA.S223837

Zhu, Y., Zhou, Y., Zhang, L., Zhang, J., and Lin, J. (2017). Efficacy of interventions for adherence to the immunosuppressive therapy in kidney transplant recipients: a meta-analysis and systematic review. *J. Invest. Med.* 65, 1049–1056. doi: 10.1136/jim-2016-000265

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Shi, Liu, Liu, Zhang, Yu, Jin, Shang and Fu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.